APPLICANT FACSIMILE OF FORM PTO-1449 (Rev. 2-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
	RPI-011CPCN	09/995519
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	
	Boussiotis, V.A., *et al.*	
	FILING DATE	GROUP
	November 28, 2001	1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,116,964	5/26/92	Capon et al	536	27	
	AB	5,434,131	7/18/95	Linsley et al.	514	2	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AC	WO 90/05541	5/31/90	PCT				
	AD	WO 91/11194	8/8/91	PCT				
	AE	WO 92/00092	1/9/92	PCT				
	AF	WO 92/15671	9/17/92	PCT				
	AG	0503646 A1	12/3/92	EPO				
	AH	WO 93/00431	1/7/93	PCT				
	AI	WO 93/06852	4/15/93	PCT				
	AJ	WO 93/06866	4/15/93	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	AK	Azuma, M., et al., "B70 Antigen is a Second Ligand for CTLA-4 and CD28," *Nature*, vol. 366, 76-79 (1993);
	AL	Bell, G. and Imboden, J., "CD2 and the Regulation of T Cell Anergy," *The Journal of Immunology*, 2805-2807 (1995);
	AM	Beverly, B., et al., "Reversal of in Vitro T Cell Clonal Anergy by IL-2 Stimulation," *International Immunology*, vol. 4, no. 6, 661-671 (1992);
	AN	Bierer, B., et al., "Interaction of CD2 with its Ligand, LFA-3, in Human T Cell Proliferation," *The Journal of Immunology*, vol. 140, no. 10, 3358-3363 (1988);
	AO	Bierer, B., et al., "Synergistic T Cell Activation Via the Physiological Ligands for CD2 and the T Cell Receptor," *J. Exp. Med.*, vol. 168, 1145-1156 (1988);
	AP	Boussiotis, V., et al., "B7 but not Intercellular Adhesion Molecule-1 Costimulation Prevents the Induction of Human Alloantigen-specific Tolerance," *J. Exp. Med.*, vol. 178, 1753-1763 (1993);
	AQ	Boussiotis, V., et al., "CD2 is Involved in Maintenance and Reversal of Human Alloantigen-specific Clonal Anergy," *J. Exp. Med.*, vol. 180, 1665-1673 (1994);
	AR	Boussiotis, V., et al., "Human Alloantigen Specific Clonal Anergy to Lymphoblastoid Cells is Reversed Following Culture with IL-2 or IL-4," *Blood*, vol. 82, 304A (1993);
	AS	Brottier, P., et al., "T Cell Activation Via CD2 [T, gp50] Molecules: Accessory Cells are Required to Trigger T Cell Activation Via CD2-D66 Plus CD2-9.6/T11, Epitopes," *The Journal of Immunology*, vol. 135, no. 3, 1624-1631 (1985);

Examiner	Date Considered
Phillip B. Gambel	4/11/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		09/995519
	FILING DATE November 28, 2001	GROUP 1644

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	BA		Dustin, M., et al., "Anchoring Mechanisms for LFA-3 Cell Adhesion Glycoprotein at Membrane Surface," *Nature*, vol. 329, 846-848 (1987);
	BB		Freedman, A., et al., "B7, a B Cell-Restricted Antigen that Identifies Preactivated B Cells," Division of Tumor Immunology, Dana-Farber Cancer Institute and the Department of Medicine, 3260-3267 (1987);
	BC		Freeman, G., et al., "B7, a new Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells," *The Journal of Immunology*, vol. 143, no. 8, 2714-2722 (1989);
	BD		Freeman, G., et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation," *Science*, vol. 262, 909-911 (1993);
	BE		Freeman, G., et al., "Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production," *The Journal of Experimental Medicine*, vol. 178, 2185-2192 (1993);
	BF		Freeman, G., et al., "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7," *J. Exp. Med.*, vol. 174, 625-631 (1991);
	BG		Freeman, G., et al., "Uncovering of Functional Alternative CTLA-4 Counter-Receptor in B7-Deficient Mice," *Science*, vol. 262, 907-909 (1993);
	BH		Gimmi, C., et al., "B-cell Surface Antigen B7 Provides a Costimulatory Signal that Induces T Cells to Proliferate and Secrete Interleukin 2," *Proc. Natl. Acad. Sci. USA*, vol. 88, 6575-6579 (1991);
	BI		Gimmi, C., et al., "Human T-cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation," *Proc. Natl. Acad. Sci. USA*, vol. 90, 6586-6590 (1993);
	BJ		Harding, F., et al., "CD28-mediated Signaling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T-cell Clones," *Nature*, vol. 356, 607-609 (1992);
	BK		Hathcock, K., et al., "Identification of an Alternative CTLA-4 Ligand Costimulatory for T Cell Activation," *Science*, vol. 262, 905-907 (1993);
	BL		Koyasu, S., et al., "Role of Interaction of CD2 Molecules with Lymphocyte Function-associated Antigen 3 in T-cell Recognition of Nominal Antigen," *Proc. Natl. Acad. Sci. USA*, vol. 87, 2603-2607 (1990);
	BM		Lenschow, D., et al., "Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4Ig," *Science*, vol. 257, 789-791 (1992);
	BN		Lin, H., et al., "Long-Term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4Ig Plus Donor-specific Transfusion," *J. Exp. Med.*, vol.178, 1801-1806 (1993);
	BO		Linsley, P., et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation," *J. Exp. Med.*, vol. 173, 721-730 (1991);
	BP		Linsley, P., et al., "Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule," *Science*, vol. 257, 792-795 (1992);
	BQ		Meuer, S., et al., "An Alternative Pathway of T-Cell Activation: A Functional Role for the 50 kd T11 Sheep Erythrocyte Receptor Protein," *Cell*, vol. 36, 897-906 (1984);
	BR		Moingeon, P., et al., "CD2-mediated Adhesion Facilitates T Lymphocyte Antigen Recognition Function," *Nature*, vol. 339, 312-314 (1989);

Examiner	PHILIP CAMBELL	Date Considered	4/11/05

*EXAMINER			Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	09/995519
	APPLICANT: **Boussiotis, V.A., *et al.***
	FILING DATE: **November 28, 2001** / GROUP: **1644**

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	CA		Pepinsky, R., et al., "The Increased Potency of Cross-linked Lymphocyte Function-associated Antigen-3 (LFA-3) Multimers is a Direct Consequence of Changes in Valency," *The Journal of Biological Chemistry*, vol. 266, no. 27, 18244-18249 (1991);
	CB		Seed, B., "An LFA-3 cDNA Encodes a Phospholipid-linked Membrane Protein Homologous to its Receptor CD2," *Nature*, vol. 329, 840-842 (1987);
	CC		Selvaraj, P., et al., "The T Lymphocyte Glycoprotein CD2 Binds the Cell Surface Ligand LFA-3," *Nature*, vol. 326, 400-403 (1987);
	CD		Tan, P., et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with its Natural Ligand B7/BB1," *J. Exp. Med.*, vol. 177, 165-173 (1993);
	CE		Van Gool, S., et al., "The Combination of Anti-B7 Monoclonal Antibody and Cyclosporin A Induces Alloantigen-specific Anergy During a Primary Mixed Lymphocyte Reaction," *J. Exp. Med.*, vol. 179, 715-720 (1994);
	CF		Wallner, B., et al., "Primary Structure of Lymphocyte Function-Associated Antigen 3 (LFA-3) The Ligand of the T Lymphocyte CD2 Glycoprotein," *Journal of Experimental Medicine*, vol. 166, 923-932 (1987);
	CG		Yang, S., et al., "A Common Pathway for T Lymphocyte Activation Involving Both the CD3-Ti Complex and CD2 Sheep Erythrocyte Receptor Determinants," *The Journal of Immunology*, vol. 137, no. 4, 1097-1100 (1986).
	CH		
	CI		
	CJ		
	CK		
	CL		
	CM		
	CN		
	CO		
	CP		
	CQ		
	CR		
	CS		

Examiner			Date Considered 4/11/05
*EXAMINER			Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.